Guggenheim Boosts Krystal Biotech (NASDAQ:KRYS) Price Target

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its target price hoisted by Guggenheim from $101.00 to $130.00 in a research report released on Monday morning, The Fly reports. Other equities analysts also recently issued reports about the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $133.00 to $148.00 in a […]

Related Keywords

Arizona , United States , America , William Blair , Daniel Janney , Stifel Nicolaus , Suma Krishnan , Group Plc , Goldman Sachs Group , Krystal Biotech Company Profile , Manufacturers Life Insurance Company , Nasdaq , Proshare Advisors , Krystal Biotech Inc , Allspring Global Investments Holdings , Krystal Biotech , Get Rating , Director Daniel Janney , Global Investments Holdings , State Retirement System , General Group Plc , Share Advisors , Krystal Biotech Daily , Nasdaq Krys , Krys , Medical , Boost Price Target , Guggenheim ,